Briacell Therapeutics Corp (BCTX)

$3.49 -0.23 (-6.18%)
Market Cap 26.97M
Revenue (ttm) 0.00
Net Income (ttm) -26.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 491,900
Avg Vol 213,076
Day's Range N/A - N/A
Shares Out 7.25M
Stochastic %K 38%
Beta 1.26
Analysts Strong Buy
Price Target $40.00

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 921 1810
Fax: 604 921 1898
Address:
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada
Goodstockday
Goodstockday May. 23 at 12:19 PM
$BCTX The next big event for this stock is the interim phase 3 readout. I do not expect that until November or December. We might even need to wait until 2027 if the outcome is especially good. The phase 2 data indicates we should expect good results. The market cap is quite low. I like the risk vs. reward here. Yet, this one will require patience.
0 · Reply
JediGreen
JediGreen May. 23 at 6:31 AM
$BCTX briacell therapeutics buyout potential - Google Search https://www.google.com/search?q=briacell+therapeutics+buyout+potential&sca_esv=b95ffecbfaf145e4&udm=50&fbs=ADc_l-YIDyOa9njRppQkDyQFqQvysFahwxRkH3Kr3Q841_srcotGKaj3uVWhlFwsjLbKE_RmT445O7V7ncobvFcrKIs31VVX9sdvXtYsd6WayuxOAKTe98h5lLYwQX5Wx8sjKYVVyc_ZGCas7c26iwT7bd-tu2KHFCcMZ1Sf4u0SPo-ctYiO9np8yvzb2oztYYjv7eCMQwgSZpQwy09hxC0S8XTj-85XzC5RWInsRvF0rMM6j-9CVbU&aep=1&ntc=1&sa=X&ved=2ahUKEwikntbf486UAxWerIkEHZN2B1UQ2J8OegQIDRAE&biw=430&bih=721&dpr=3&mstk=AUtExfB0Ya-8AchtTDl7Hpbae8px10d-Us9bjyHD8VT56UK7fv4dxR3yMCmSkR4GEzWkNVtBmTt4BNPNfEp5JeB27-J6HdNZkTwD2NNGbAe3NHi1v6Yykn7aftTINtftRPg81GuDn9mgKrFhdporok7ErhPuDBLy056hq8Y&csuir=1
0 · Reply
JediGreen
JediGreen May. 22 at 7:11 PM
$BCTX This Is How The SMART Money Manipulates YOUR Trades! (Leaked Video) - YouTube https://www.youtube.com/watch?v=RKGaXB4AyWs
0 · Reply
ZacksResearch
ZacksResearch May. 22 at 6:37 PM
$BCTX just dropped survival data that could turn heads at ASCO 👀 📈 Phase 2 patients who started CPI in cycle 1 saw median OS of 13.3 months vs. 7.4 months with delayed CPI 🧬 The Phase 3-selected formulation delivered 16.6 months median OS with 52% 12-month survival ✅ No treatment-related discontinuations or unexpected safety signals reported BriaCell is also highlighting preserved quality of life and potential home self-administration in its ongoing Phase 3 Bria-ABC study — a big deal for heavily pretreated metastatic breast cancer patients. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/BCTX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38186&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38186
0 · Reply
SmallCapGrowth
SmallCapGrowth May. 22 at 6:12 PM
BB's Stock Haven : $BCTX is pleased to announce positive cl... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177632559 via @Investors_Hub
0 · Reply
SmallCapGrowth
SmallCapGrowth May. 22 at 6:11 PM
Breaking: BriaCell $BCTX reports positive Bria-IMT™ data at ASCO 2026 — Phase 2 median OS 16.6 months & supportive Phase 3 QOL and biomarker findings. Full story: https://wix.to/gMgrDdd #ASCO2026 #Biotech #ClinicalTrials
0 · Reply
negligiblecat
negligiblecat May. 22 at 5:52 PM
$BCTX Considering that they have virtually no money and that they have been guiding 2026 instead of 1h 26 as they originally did a few months back hints that its likely coming Q3 or Q4. Their cash will be very low by then so its not impossible they will have to dilute even more by then.
1 · Reply
SmallCapGrowth
SmallCapGrowth May. 22 at 5:31 PM
$BCTX BriaCell’s Bria‑IMT™ data at ASCO 2026 look promising — Phase 2 median OS 16.6 months, positive QOL in Phase 3, and biomarker confirmation of response predictors. Read more: https://wix.to/k2eI7hA #BCTX #ASCO2026 #oncology
0 · Reply
SmallCapGrowth
SmallCapGrowth May. 22 at 4:59 PM
which one is next? : $BCTX BriaCell at ASCO 2026: Bria-IMT https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177632815 via investorshub
0 · Reply
SmallCapGrowth
SmallCapGrowth May. 22 at 4:41 PM
$BCTX BriaCell at ASCO 2026: Bria-IMT™ shows a Phase 2 median OS of 16.6 months and positive Phase 3 QOL data in heavily pre-treated MBC patients. Biomarker analyses support response predictors. Full story: https://wix.to/X0GjMKI #ASCO2026 #BriaCell #BioTech #CancerResearch
0 · Reply
Latest News on BCTX
BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

2026-05-22T13:27:19.000Z - 1 day ago

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

BriaCell announces data from Bria-IMT at ASCO 2026

2026-05-22T11:49:02.000Z - 1 day ago

BriaCell announces data from Bria-IMT at ASCO 2026

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Fri, 22 May 2026 07:30:00 -0400 - 1 day ago

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

Fri, 15 May 2026 07:30:00 -0400 - 8 days ago

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

2026-05-14T15:31:53.000Z - 8 days ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

Thu, 14 May 2026 07:30:00 -0400 - 9 days ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T16:39:28.000Z - 9 days ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

2026-05-13T14:41:55.000Z - 9 days ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Wed, 13 May 2026 07:30:00 -0400 - 10 days ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Tue, 12 May 2026 07:30:00 -0400 - 11 days ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Thu, 07 May 2026 07:30:00 -0400 - 16 days ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

2026-05-07T04:03:56.000Z - 16 days ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Wed, 06 May 2026 07:30:00 -0400 - 17 days ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

Mon, 27 Apr 2026 07:30:00 -0400 - 26 days ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T13:28:43.000Z - 4 weeks ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

BriaCell presents anti-cancer activity of Bria-OTS

2026-04-21T11:54:23.000Z - 4 weeks ago

BriaCell presents anti-cancer activity of Bria-OTS

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

Tue, 21 Apr 2026 07:30:00 -0400 - 4 weeks ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T13:32:04.000Z - 4 weeks ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

2026-04-20T11:41:56.000Z - 4 weeks ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Mon, 20 Apr 2026 07:30:00 -0400 - 4 weeks ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

Tue, 31 Mar 2026 16:05:00 -0400 - 7 weeks ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T13:30:56.000Z - 2 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

BriaCell to present four posters at the 2026 AACR

2026-03-18T11:42:55.000Z - 2 months ago

BriaCell to present four posters at the 2026 AACR

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Wed, 18 Mar 2026 07:30:00 -0400 - 2 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Tue, 10 Mar 2026 07:30:00 -0400 - 2 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 2 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:51:30.000Z - 3 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

2026-02-18T22:35:25.000Z - 3 months ago

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

Wed, 18 Feb 2026 17:30:00 -0500 - 3 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

2026-02-17T12:40:59.000Z - 3 months ago

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Tue, 17 Feb 2026 07:30:00 -0500 - 3 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

2026-01-28T13:30:56.000Z - 4 months ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

BriaCell says patient images show regression, resolution of metastsized tumors

2026-01-28T12:40:40.000Z - 4 months ago

BriaCell says patient images show regression, resolution of metastsized tumors

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

Wed, 28 Jan 2026 07:30:00 -0500 - 4 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

2026-01-27T13:32:37.000Z - 4 months ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

2026-01-27T12:41:04.000Z - 4 months ago

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Tue, 27 Jan 2026 07:30:00 -0500 - 4 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-19T16:00:45.000Z - 4 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

2026-01-16T13:58:57.000Z - 4 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Thu, 15 Jan 2026 16:05:00 -0500 - 4 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

What's Going On With BriaCell Therapeutics Stock Wednesday?

2026-01-14T11:36:30.000Z - 4 months ago

What's Going On With BriaCell Therapeutics Stock Wednesday?

BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

2026-01-14T11:19:44.000Z - 4 months ago

BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

2026-01-14T10:55:53.000Z - 4 months ago

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

BriaCell Therapeutics (BCTX) Launches $30M Public Offering

2026-01-14T06:56:44.000Z - 4 months ago

BriaCell Therapeutics (BCTX) Launches $30M Public Offering

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

Tue, 13 Jan 2026 21:00:00 -0500 - 4 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

BCTX Surges On Positive Clinical Response In Metastatic Cancer Immunotherapy Study

2026-01-13T20:32:32.000Z - 4 months ago

BCTX Surges On Positive Clinical Response In Metastatic Cancer Immunotherapy Study

BriaCell Therapeutics trading resumes

2026-01-13T14:41:11.000Z - 4 months ago

BriaCell Therapeutics trading resumes

BriaCell Therapeutics trading halted, volatility trading pause

2026-01-13T14:35:29.000Z - 4 months ago

BriaCell Therapeutics trading halted, volatility trading pause

BriaCell Surge Above 50%; What's The Buzz?

2026-01-13T14:08:02.000Z - 4 months ago

BriaCell Surge Above 50%; What's The Buzz?

BriaCell (BCTX) Reports Impressive Lung Metastasis Resolution in Cancer Trial

2026-01-13T12:53:09.000Z - 4 months ago

BriaCell (BCTX) Reports Impressive Lung Metastasis Resolution in Cancer Trial

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

2026-01-13T12:35:49.000Z - 4 months ago

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Jan 13, 2026, 7:30 AM EST - 4 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

Dec 18, 2025, 7:30 AM EST - 5 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

BriaCell presents Phase 2, Phase 3 data on Bria-IMT at SABCS 2025

2025-12-10T12:41:29.000Z - 5 months ago

BriaCell presents Phase 2, Phase 3 data on Bria-IMT at SABCS 2025

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

Dec 10, 2025, 7:30 AM EST - 5 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

BriaCell announces Phase 3 patient enrollment on track for 1H26 data readout

2025-12-09T12:35:35.000Z - 5 months ago

BriaCell announces Phase 3 patient enrollment on track for 1H26 data readout

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Dec 9, 2025, 7:30 AM EST - 5 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

BriaCell to present Phase 2 survival, Phase 3 data at SABCS 2025

2025-12-02T12:36:29.000Z - 6 months ago

BriaCell to present Phase 2 survival, Phase 3 data at SABCS 2025

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Dec 2, 2025, 7:30 AM EST - 6 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 6 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

BriaCell, Receptor.AI collaborate on AI small molecular cancer therapeutics

2025-11-20T12:40:35.000Z - 6 months ago

BriaCell, Receptor.AI collaborate on AI small molecular cancer therapeutics

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 20, 2025, 7:30 AM EST - 6 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 18, 2025, 7:30 AM EST - 6 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

BriaCell presents anti-cancer activity of Bria-OTS at SITC 2025

2025-11-07T12:41:48.000Z - 7 months ago

BriaCell presents anti-cancer activity of Bria-OTS at SITC 2025

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 7, 2025, 7:30 AM EST - 7 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Nov 4, 2025, 7:30 AM EST - 7 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:50 AM EDT - 7 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 21, 2025, 7:30 AM EDT - 7 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 20, 2025, 7:30 AM EDT - 7 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 7 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Oct 3, 2025, 7:30 AM EDT - 8 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 26, 2025, 7:30 AM EDT - 9 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 25, 2025, 7:30 AM EDT - 9 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 21, 2025, 12:00 PM EDT - 9 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Aug 13, 2025, 7:30 AM EDT - 10 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 31, 2025, 7:30 AM EDT - 10 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 30, 2025, 7:30 AM EDT - 10 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 29, 2025, 7:30 AM EDT - 10 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 25, 2025, 7:30 AM EDT - 10 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 16, 2025, 4:05 PM EDT - 11 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 11 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 15, 2025, 7:30 AM EDT - 11 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 11 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 10, 2025, 7:30 AM EDT - 11 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Jul 9, 2025, 7:30 AM EDT - 11 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 8, 2025, 7:30 AM EDT - 11 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Goodstockday
Goodstockday May. 23 at 12:19 PM
$BCTX The next big event for this stock is the interim phase 3 readout. I do not expect that until November or December. We might even need to wait until 2027 if the outcome is especially good. The phase 2 data indicates we should expect good results. The market cap is quite low. I like the risk vs. reward here. Yet, this one will require patience.
0 · Reply
JediGreen
JediGreen May. 23 at 6:31 AM
$BCTX briacell therapeutics buyout potential - Google Search https://www.google.com/search?q=briacell+therapeutics+buyout+potential&sca_esv=b95ffecbfaf145e4&udm=50&fbs=ADc_l-YIDyOa9njRppQkDyQFqQvysFahwxRkH3Kr3Q841_srcotGKaj3uVWhlFwsjLbKE_RmT445O7V7ncobvFcrKIs31VVX9sdvXtYsd6WayuxOAKTe98h5lLYwQX5Wx8sjKYVVyc_ZGCas7c26iwT7bd-tu2KHFCcMZ1Sf4u0SPo-ctYiO9np8yvzb2oztYYjv7eCMQwgSZpQwy09hxC0S8XTj-85XzC5RWInsRvF0rMM6j-9CVbU&aep=1&ntc=1&sa=X&ved=2ahUKEwikntbf486UAxWerIkEHZN2B1UQ2J8OegQIDRAE&biw=430&bih=721&dpr=3&mstk=AUtExfB0Ya-8AchtTDl7Hpbae8px10d-Us9bjyHD8VT56UK7fv4dxR3yMCmSkR4GEzWkNVtBmTt4BNPNfEp5JeB27-J6HdNZkTwD2NNGbAe3NHi1v6Yykn7aftTINtftRPg81GuDn9mgKrFhdporok7ErhPuDBLy056hq8Y&csuir=1
0 · Reply
JediGreen
JediGreen May. 22 at 7:11 PM
$BCTX This Is How The SMART Money Manipulates YOUR Trades! (Leaked Video) - YouTube https://www.youtube.com/watch?v=RKGaXB4AyWs
0 · Reply
ZacksResearch
ZacksResearch May. 22 at 6:37 PM
$BCTX just dropped survival data that could turn heads at ASCO 👀 📈 Phase 2 patients who started CPI in cycle 1 saw median OS of 13.3 months vs. 7.4 months with delayed CPI 🧬 The Phase 3-selected formulation delivered 16.6 months median OS with 52% 12-month survival ✅ No treatment-related discontinuations or unexpected safety signals reported BriaCell is also highlighting preserved quality of life and potential home self-administration in its ongoing Phase 3 Bria-ABC study — a big deal for heavily pretreated metastatic breast cancer patients. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/BCTX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-38186&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_38186
0 · Reply
SmallCapGrowth
SmallCapGrowth May. 22 at 6:12 PM
BB's Stock Haven : $BCTX is pleased to announce positive cl... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177632559 via @Investors_Hub
0 · Reply
SmallCapGrowth
SmallCapGrowth May. 22 at 6:11 PM
Breaking: BriaCell $BCTX reports positive Bria-IMT™ data at ASCO 2026 — Phase 2 median OS 16.6 months & supportive Phase 3 QOL and biomarker findings. Full story: https://wix.to/gMgrDdd #ASCO2026 #Biotech #ClinicalTrials
0 · Reply
negligiblecat
negligiblecat May. 22 at 5:52 PM
$BCTX Considering that they have virtually no money and that they have been guiding 2026 instead of 1h 26 as they originally did a few months back hints that its likely coming Q3 or Q4. Their cash will be very low by then so its not impossible they will have to dilute even more by then.
1 · Reply
SmallCapGrowth
SmallCapGrowth May. 22 at 5:31 PM
$BCTX BriaCell’s Bria‑IMT™ data at ASCO 2026 look promising — Phase 2 median OS 16.6 months, positive QOL in Phase 3, and biomarker confirmation of response predictors. Read more: https://wix.to/k2eI7hA #BCTX #ASCO2026 #oncology
0 · Reply
SmallCapGrowth
SmallCapGrowth May. 22 at 4:59 PM
which one is next? : $BCTX BriaCell at ASCO 2026: Bria-IMT https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177632815 via investorshub
0 · Reply
SmallCapGrowth
SmallCapGrowth May. 22 at 4:41 PM
$BCTX BriaCell at ASCO 2026: Bria-IMT™ shows a Phase 2 median OS of 16.6 months and positive Phase 3 QOL data in heavily pre-treated MBC patients. Biomarker analyses support response predictors. Full story: https://wix.to/X0GjMKI #ASCO2026 #BriaCell #BioTech #CancerResearch
0 · Reply
SmallCapGrowth
SmallCapGrowth May. 22 at 4:31 PM
MOMO'S BREAKOUT BOARD : Smart money watches inflection points. $BCTX:.... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177632652 via @Investors_Hub
1 · Reply
_rags_2_riches_
_rags_2_riches_ May. 22 at 4:29 PM
$BCTX Momentum downward. Subpar results especially when compared to its peer group.
4 · Reply
Shindan
Shindan May. 22 at 4:29 PM
$BCTX What kind of stock is this?
1 · Reply
Kirubin
Kirubin May. 22 at 4:17 PM
$BCTX sensitive morons! it is all about making money fucking sheep!😂💀🐏🐏🐏🫡
0 · Reply
SmallCapGrowth
SmallCapGrowth May. 22 at 4:08 PM
Smart money watches inflection points. $BCTX: ✔ Phase 2 survival data established baseline ✔ Phase 3 QoL + biomarker validation ✔ ASCO = institutional visibility This is a classic biotech setup. 👉 News here: https://bit.ly/4dGr7Li #SmallCap #MicroCap #StockMarket #Alpha @SmallCapVoice
0 · Reply
SmallCapGrowth
SmallCapGrowth May. 22 at 3:51 PM
BriaCell Therapeutics Corp ( $BCTX ): $BCTX just dropped ASCO 2026 clinical d... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177632592 via @Investors_Hub @smallcapvoice @BriaCell
0 · Reply
SmallCapGrowth
SmallCapGrowth May. 22 at 3:48 PM
$BCTX just dropped ASCO 2026 clinical data —and it’s not noise. ✅ Phase 2 median OS: 16.6 months ✅ Positive quality-of-life data in Phase 3 ✅ Biomarkers confirming response signals This is a late-stage oncology play with momentum. 👉 https://bit.ly/4dGr7Li #biotech #stocks
1 · Reply
SmallCapGrowth
SmallCapGrowth May. 22 at 3:39 PM
$BCTX is pleased to announce positive clinical data from three clinical data poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting, taking place May 29–June 2, 2026 at McCormick Place, Chicago, Illinois. Read more: https://www.globenewswire.com/news-release/2026/05/22/3300068/0/en/briacell-presentations-highlight-positive-clinical-data-for-bria-imt-at-asco-2026.html #ASCO2026 #Oncology #Biotech @smallcapvoice @BriaCell
0 · Reply
DunkenInvest
DunkenInvest May. 22 at 3:10 PM
$BCTX I dont understand how so many Yap about really good reports, but every time theres news, it goes RED. Don't blame the shorts every time, it looks like there's more bulls than bears in here, so bulls should always have the upper hand... Unless they're extremely poor 🤷🏼
2 · Reply
Goodstockday
Goodstockday May. 22 at 2:58 PM
$BCTX In the company press release today, they report 16.6 month median OS in the phase 2 study for those that got the phase 3 formulation. That is a very strong number for this population! Anything in that ballpark for the phase 3 and this is a big win!
1 · Reply
JediGreen
JediGreen May. 22 at 2:10 PM
$BCTX https://youtube.com/shorts/Q64BRqTHaR4?si=5-EmzMILbYVYJQ1Q
0 · Reply
BHWinehouse
BHWinehouse May. 22 at 1:54 PM
$BCTX So when it goes up .66 we're all geniuses. You're some type of special.
1 · Reply